GeneDx Reports Q1 2026 Earnings with Revenue Below Expectations
GeneDx (WGS) reported Q1 2026 earnings with total revenue of $102.3 million, below internal expectations due to lower reimbursement rates and non-core business softness. The company saw a 34% year-over-year growth in exome and genome test volume but faced challenges with its blended average reimbursement rate (ARR), which was $200 below projections. The full-year revenue guidance was revised downward to $475 million to $490 million.
Tickers: $WGS
Topics: business performance earnings report financial guidance reimbursement rates revenue growth